Yale Cancer Center

Running trials

• Recruiting

  Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes

  NCT07672769· Phase 2· Source

• Recruiting

  A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  NCT07701941· Phase 1/2· Source

• Recruiting

  SI-B036-ST-101 in Advanced/Metastatic Solid Tumors

  NCT07857616· Phase 1· Source

• Recruiting

  A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  NCT07101328· Phase 1· Source

• Recruiting

  A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

  NCT07578571· Phase 1· Source

• Recruiting

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· Phase 1· Source

• Recruiting

  Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

  NCT07326566· Phase 2· Source

• Recruiting

  A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

  NCT07567846· Phase 1/2· Source

• Recruiting

  A Study of GEN1106 in Participants With Solid Tumors

  NCT07416123· Phase 1· Source

• Recruiting

  A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

  NCT07503808· Phase 1· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Source

• Recruiting

  Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

  NCT07349537· Phase 1· Source

• Recruiting

  A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

  NCT07361562· Phase 1· Source

• Enrolling by invitation

  Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic

  NCT07417774· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Source

• Enrolling by invitation

  A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

  NCT07218003· Phase 1· Source

• Recruiting

  M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

  NCT07166601· Phase 1· Source

• Recruiting

  A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

  NCT07169734· Phase 1/2· Source

• Recruiting

  Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

  NCT07098988· Phase 2· Source

• Active, not recruiting

  Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

  NCT07021066· Phase 1· Source

• Recruiting

  Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis

  NCT06950385· Phase 3· Source

• Active, not recruiting

  An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

  NCT06991556· Phase 2· Source

• Recruiting

  Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer

  NCT06959082· Phase 2· Source

• Recruiting

  Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

  NCT07080242· Phase 1· Source

• Recruiting

  A Study of PHST001 in Advanced Solid Tumors

  NCT06840886· Phase 1· Source

• Recruiting

  A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

  NCT07029399· Phase 1· Source

• Recruiting

  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  NCT06731478· Phase 3· Source

• Recruiting

  SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

  NCT06743126· Phase 3· Source

• Recruiting

  First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

  NCT06657222· Phase 1/2· Source

• Recruiting

  Revumenib in Combination With 7+3 + Midostaurin in AML

  NCT06313437· Phase 1· Source

• Recruiting

  A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

  NCT06638307· Phase 1· Source

• Active, not recruiting

  A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

  NCT06607185· Phase 1· Source

• Recruiting

  QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

  NCT06551116· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT06497556· Phase 3· Source

• Recruiting

  A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

  NCT06246916· Phase 3· Source

• Recruiting

  Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  NCT06393374· Phase 3· Source

• Recruiting

  Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  NCT06343402· Phase 1· Source

• Active, not recruiting

  A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

  NCT05973487· Phase 1· Source

• Recruiting

  A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

  NCT06385080· Phase 1/2· Source

• Recruiting

  The SUGAR Study; SBRT and Relugolix) for Prostate Cancer

  NCT06111781· Phase 2· Source

• Recruiting

  A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

  NCT06312176· Phase 3· Source

• Recruiting

  A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  NCT06172478· Phase 2· Source

• Recruiting

  A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

  NCT06196203· Phase 2· Source

• Recruiting

  A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT06153251· Phase 1· Source

• Recruiting

  A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

  NCT06179069· Phase 1· Source

• Recruiting

  Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

  NCT06100705· Phase 2· Source

• Active, not recruiting

  A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

  NCT06003231· Phase 2· Source

• Recruiting

  A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

  NCT06084936· Phase 3· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

  NCT05968326· Phase 2· Source

• Recruiting

  A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

  NCT05902988· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer19 recruiting
• Head and neck cancer9 recruiting
• Triple-negative breast cancer9 recruiting
• Prostate cancer8 recruiting
• Colorectal cancer7 recruiting
• Metastatic breast cancer6 recruiting
• Endometrial cancer5 recruiting
• Gastric and esophageal cancer5 recruiting
• Melanoma5 recruiting
• Ovarian cancer5 recruiting
• Bladder cancer4 recruiting
• Pancreatic cancer4 recruiting
• Follicular lymphoma3 recruiting
• Liver and biliary tract cancer3 recruiting
• Mantle cell lymphoma3 recruiting
• Cervical cancer2 recruiting
• Childhood cancers2 recruiting
• Glioblastoma2 recruiting
• Multiple myeloma2 recruiting
• Myelodysplastic syndromes2 recruiting
• Sarcoma2 recruiting
• Acute myeloid leukemia1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Kidney cancer1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Thyroid cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

  NCT06714617· Phase 1· Source

• Recruiting

  A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors

  NCT06747585· Phase 1/2· Source

• Recruiting

  A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors

  NCT06326411· Phase 1· Source

• Completed

  Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT06058793· Phase 3· Source

• Withdrawn

  Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

  NCT06180863· Phase 2· Source

• Recruiting

  Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

  NCT05974150· Source

• Recruiting

  Exercise in Metastatic Breast Cancer: EMBody

  NCT05468034· Source

• Completed

  A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

  NCT05753722· Phase 1· Source

• Completed

  Study Of ATRN-119 In Patients With Advanced Solid Tumors

  NCT04905914· Phase 1/2· Source

• Terminated

  A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

  NCT05529316· Phase 2· Source

• Recruiting

  A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

  NCT05548296· Phase 2· Source

• Terminated

  Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

  NCT05267106· Phase 2· Source

• Terminated

  A Study of SGN-ALPV in Advanced Solid Tumors

  NCT05229900· Phase 1· Source

• Completed

  A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)

  NCT05231746· Phase 1· Source

• Terminated

  Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

  NCT05275439· Phase 1· Source

• Completed

  Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

  NCT04815720· Phase 1/2· Source

• Terminated

  A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors

  NCT04875806· Phase 1/2· Source

• Completed

  An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

  NCT04660812· Phase 1/2· Source

• Completed

  Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

  NCT04902872· Phase 1/2· Source

• Terminated

  Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors

  NCT04931823· Phase 1· Source

• Terminated

  Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant

  NCT04511130· Phase 2· Source

• Completed

  A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

  NCT04495257· Phase 1· Source

• Terminated

  A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  NCT04459715· Phase 3· Source

• Completed

  Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

  NCT04191616· Phase 2· Source

• Terminated

  A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

  NCT04254107· Phase 1· Source

• Completed

  A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer

  NCT04137289· Phase 1· Source

• Completed

  A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

  NCT04294810· Phase 3· Source

• Terminated

  Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

  NCT04234113· Phase 1· Source

• Completed

  Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

  NCT03778931· Phase 3· Source

• Completed

  Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

  NCT03820986· Phase 3· Source

• Completed

  Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

  NCT03739931· Phase 1· Source

• Completed

  Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

  NCT03674567· Phase 1/2· Source

• Completed

  Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

  NCT03258931· Phase 3· Source

• Completed

  Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

  NCT03502668· Phase 1/2· Source

• Completed

  APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma

  NCT03502330· Phase 1· Source

• Completed

  Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

  NCT03511664· Phase 3· Source

• Completed

  A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

  NCT03088878· Phase 1/2· Source

• Completed

  Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

  NCT03358472· Phase 3· Source

• Terminated

  A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

  NCT03288545· Phase 1/2· Source

• Completed

  Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

  NCT03221426· Phase 3· Source

• Completed

  Gain-framed Messages and NRT for Lung Cancer Screening Patients

  NCT03069924· Phase 2· Source

• Completed

  Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer

  NCT03072238· Phase 3· Source

• Completed

  Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

  NCT02621398· Phase 1· Source

• Completed

  Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

  NCT02360579· Phase 2· Source

• Terminated

  Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

  NCT02031419· Phase 1· Source

• Completed

  S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

  NCT01359592· Phase 2· Source

• Completed

  Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

  NCT00309985· Phase 3· Source

Trial sites

• Yale Cancer Center120 trials
• Yale Cancer Center - New Haven1 trial
• Yale Cancer Center (Site 0016)1 trial
• Yale Cancer Center (Site 0053)1 trial
• Yale Cancer Center (Site 0060)1 trial
• Yale Cancer Center (Site 0061)1 trial
• Yale Cancer Center (Site 0709)1 trial
• Yale Cancer Centre1 trial
• Yale Comprehensive Cancer Center4 trials
• Yale University School of Medicine - Yale Cancer Center8 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Kidney cancer42 works · 6 trials
• Metastatic breast cancer40 works · 13 trials
• Triple-negative breast cancer29 works · 13 trials
• Acute myeloid leukemia23 works · 8 trials
• Myelodysplastic syndromes20 works · 5 trials
• Diffuse large B-cell lymphoma11 works · 4 trials